摘要
目的:探讨布地奈德福莫特罗吸入剂治疗支气管哮喘缓解期的疗效及对患者炎症因子的影响。方法:收集2016年5—2017年5月我院收治的支气管哮喘缓解期患者共86例,按随机数字表法分成两组,各43例。对照组给予茶碱缓释片(0.1 g,bid)、孟鲁司特钠(10 mg,qd)治疗,研究组在对照组基础上给予布地奈德福莫特罗吸入剂(160μg/4.5μg/次,bid)治疗,均治疗3个月,比较两组临床疗效、治疗前后肺功能及炎症因子水平。结果:研究组总有效率高于对照组,差异有统计学意义(P<0.05);治疗后,两组第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、第1秒用力呼气容积占用力肺活量百分比(FEV1/FVC)均较治疗前提高,且研究组高于对照组,差异有统计学意义(P<0.05);治疗后,两组白细胞介素(IL)-4、IL-5、肿瘤坏死因子(TNF-α)均较治疗前降低,且研究组低于对照组,差异有统计学意义(P<0.05)。结论:布地奈德福莫特罗吸入剂治疗支气管哮喘缓解期的效果显著,能明显改善患者的肺功能,降低炎症因子水平,具有较高的临床价值。
Objective:To explore the efficacy of budesonide and formoterol fumarate inhalant in the treatment of bronchial asthma in remission period and its effect on inflammatory factors in the patients.Methods:86 patients with bronchial asthma in remission period admitted to our hospital from May 2016 to May 2017 were collected and randomly divided into two groups:a control group and a study group,43 cases each.The patients in the control group were treated with theophylline sustained-release tablets(0.1 g,bid)and montelukast sodium(10 mg,qd),and the patients in the study group were treated with budesonide and formoterol fumarate inhalant(160μg/4.5μg/time,bid)based on the treatment in the control group.All the patients were treated for 3 months.The clinical efficacy,lung functions and inflammatory factor levels were compared between the two groups.Results:The total effective rate in the study group was higher than that in the control group,and the difference was statistically significant(P<0.05).The levels of forced expiratory volume in one second(FEV1),forced vital capacity(FVC)and FEV1/FVC after treatment were higher than those before treatment in the two groups,and the levels in the study group were higher than those in the control group,with statistically significant differences(P<0.05).The levels of interleukin(IL)-4,IL-5 and tumor necrosis factor(TNF)-αafter treatment were lower than those before treatment,and the levels in the study group were lower than those in the control group,with statistically significant differences(P<0.05).Conclusion:Budesonide and formoterol fumarate inhalant has a significant therapeutic effect on bronchial asthma,which can significantly improve the lung functions of the patients and reduce inflammatory factor levels,and has a high clinical value.
作者
黄海臣
Huang Hai-chen(Department of Respiratory and Critical Care Medicine,Xinyang Central Hospital,Xinyang Henan 464000,China)
出处
《中国合理用药探索》
CAS
2019年第12期128-130,134,共4页
Chinese Journal of Rational Drug Use
关键词
支气管哮喘
缓解期
布地奈德福莫特罗吸入剂
炎症因子
肺功能
Bronchial Asthma
Remission Period
Budesonide and Formoterol Fumarate Inhalant
Inflammatory Factor
Lung Function
